Negative fish oil study results raise the stakes for Amarin’s capsule

Daily use of a prescription-grade fish oil pill, first marketed by GlaxoSmithKline before going generic, failed to prevent serious cardiovascular events or death in people with diabetes, according to results from a large clinical trial presented Sunday.

The negative outcome of the study, called ASCEND, adds to the growing body of scientific evidence casting doubt on the long-term heart benefit of products containing omega-3 fatty acids.

It also does no favors for Amarin, which is hoping to upend the emboldened fish oil skepticism when a large cardiovascular outcomes study of its own product Vascepa reads out in September.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In